Your search returned 4 results.

Sort
Results
1.
Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA). MedStar authors:
  • Swain, Sandra M
PMID:
  • 24129974
Year: 2013
Citation:
  • Breast Cancer Research & Treatment. 142(1):89-99, 2013 Nov.
Institution:
  • Washington Cancer Institute
Medline publication type:
  • Clinical Trial, Phase III
  • Journal Article
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't
Form of publication:
  • Journal Article
All authors:
  • Amadori D, Baselga J, Clark E, Knott A, Miles D, Ross G, Semiglazov V, Sunpaweravong P, Swain SM
2.
Safety profile of Pertuzumab with Trastuzumab and Docetaxel in patients from Asia with human epidermal growth factor receptor 2-positive metastatic breast cancer: results from the phase III trial CLEOPATRA. MedStar authors:
  • Swain, Sandra M
PMID:
  • 24869931
Year: 2014
Citation:
  • Oncologist. 19(7):693-701, 2014 Jul.
Institution:
  • Washington Cancer Institute
Form of publication:
  • Journal Article
All authors:
  • Baselga J, Chan V, Clark E, Im SA, Im YH, Knott A, Miles D, Ross G, Swain SM
3.
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. MedStar authors:
  • Kumar, Anjali S
PMID:
  • 26187751
Citation:
  • Lancet Oncology. 16(8):957-66, 2015 Aug.
Institution:
  • MedStar Washington Hospital Center
Department:
  • Surgery/Colorectal Surgery
Medline publication type:
  • Clinical Trial, Phase II
  • Journal Article
  • Multicenter Study
  • Research Support, N.I.H., Extramural
Form of publication:
  • Journal Article
All authors:
  • Avila K, Cataldo PA, Chow OS, Coutsoftides T, Dietz DW, Fichera A, Garcia-Aguilar J, Herzig DO, Hunt SR, Kumar AS, Marcet JE, Oommen S, Patil S, Polite BN, Smith DD, Stamos MJ, Ternent CA, Timing of Rectal Cancer Response to Chemoradiation Consortium, Varma MG
4.
Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients. MedStar authors:
  • Cruz, Allan-Louie
PMID:
  • 28453705
Year: 2017
Citation:
  • Annals of Oncology. 28(5):1050-1056, 2017 May 01
Institution:
  • MedStar Washington Hospital Center
Department:
  • Hematology/Oncology
Medline publication type:
  • Journal Article
Form of publication:
  • Journal Article
All authors:
  • Barr PM, Brander DM, Cheson BD, Claxton DF, Cruz AL, Daniel C, Fanning M, Foon K, Gashonia L, Goy A, Henick Bachow S, Hill BT, Howlett C, Isaac K, Kennard KH, Kiselev P, Lamanna N, Lenhart J, Mato AR, Nabhan C, Pu JJ, Schuster SJ, Skarbnik AP, Svoboda J, Timlin C, Ujjani CS, Winter AM, Yacur M, Zent CS
Pages

Powered by Koha